Windtree Announces Craig Fraser Plans To Retire From His Role As Chief Executive Officer, Effective December 1, 2024, Will Remain On The Board Of Directors Of The Company As Chairman; Board Has Appointed Jed Latkin, A Current Director Of The Company,...
Windtree Announces Craig Fraser Plans To Retire From His Role As Chief Executive Officer, Effective December 1, 2024, Will Remain On The Board Of Directors Of The Company As Chairman; Board Has Appointed Jed Latkin, A Current Director Of The Company,...
Windtree Announces Craig Fraser Plans To Retire From His Role As Chief Executive Officer, Effective December 1, 2024, Will Remain On The Board Of Directors Of The Company As Chairman; Board Has Appointed Jed Latkin, A Current Director Of The Company, To Replace Mr. Fraser As CEO
windtree宣布克雷格·弗雷泽计划于2024年12月1日退休，将继续担任公司董事会主席;董事会已任命公司现任董事杰德·拉特金接替弗雷泽先生担任首席执行官
Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that Craig Fraser plans to retire from his role as Chief Executive Officer, effective December 1, 2024, after nearly nine years of distinguished service to the Company. Mr. Fraser will remain on the Board of Directors of the Company as Chairman. The Company's Board has appointed Jed Latkin, a current director of the Company, to replace Mr. Fraser as CEO and Mr. Latkin will also remain a member of the Board.
风树治疗股份有限公司（"风树"或"公司") (纳斯达克CM: WINT)，一家专注于推进早期和晚期创新治疗关键疾病的生物技术公司，今日宣布，克雷格·弗雷泽计划于2024年12月1日退休，结束了近九年的杰出服务。弗雷泽先生将继续担任公司董事会主席。公司董事会已任命杰德·拉特金，公司现任董事，接替弗雷泽先生担任首席执行官，拉特金先生也将继续担任董事会成员。
